Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Stoke Therapeutics. The associated price target remains the same with $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the promising potential of Stoke Therapeutics. The 36-month data for Zorevunersen (STK-001) indicates a significant reduction in seizure burden and signs of disease modification, which appear to improve over time, particularly in the third year of treatment. This durability in reducing seizures is notable even for patients who began with sub-optimal loading doses, and the improvements are maintained for those on higher doses.
Additionally, the data suggests that Zorevunersen offers benefits beyond seizure reduction, with improvements in non-seizure effects that are rare with other treatments like Fintepla. The management’s evolving strategy, now more aggressive in pursuing expedited access through Breakthrough Therapy Designation, further supports the stock’s potential. The ongoing Phase 3 EMPEROR trial and the company’s valuation analysis also contribute to the positive outlook, making Stoke Therapeutics a compelling investment opportunity.
Shrader covers the Healthcare sector, focusing on stocks such as NRX Pharmaceuticals, Harrow Health, and Denali Therapeutics. According to TipRanks, Shrader has an average return of 2.6% and a 38.07% success rate on recommended stocks.
In another report released on August 14, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $19.00 price target.